China: Food and Drugs Law

drug patent linkage litigation cases, if the parties are in dispute over whether the technical solution of the originator drug falls within the protection...

As one of the world's largest drug consumer and manufacturing markets, China plays a pivotal role in global pharma patent strategies – and changes in the country's IP landscape can have profound commercial implications.

China is becoming an increasing focus for transactions in the pharmaceuticals sector with its growing investment into research and development, government support and a steady...

马库什化合物是一类基于一定基础结构的前体下...

On March 19, 2025, China's National Medical Products Administration (NMPA) released the Draft Implementing Measures and Working Procedures for Drug Clinical Trial Data Protection...

On January 23, 2025, the Anti-Monopoly and Anti-Unfair Competition Commission under China's State Council officially released the PRCAnti-Monopoly Guidelines for the Pharmaceutical Sector...

To implement the Drug Administration Law of the PRC, a draft version of the Measures for Supervision and Administration of Drug Supply was publicized in September 2019 for public opinion

The PRC Drugs Prohibition Law classifies "marijuana"—products from the plant Cannabis sativa that contain substantial amounts of tetrahydrocannabinol (THC)—as drugs and prohibits its use in any form

The Supreme People's Court ("SPC") of the People's Republic of China ("PRC") has recently promulgated the Interpretation on Several Issues Concerning the Application of Law to the Trial of Cases of Disputes over Punitive Damages in Food and Drugs ("Interpretation"), taking effect from August 22, 2024.